| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks
1 company
Teresa L. Young is See Remarks at MCRB. Teresa L. Young's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $17K at current prices.
Historically, Teresa L. Young's trades have earned a strong insider score of 72/100 across 12 rated trades. Over a 12-month horizon, 70.0% of those trades were profitable, with an average 12-month return of +17.9%.
The MCRB filings lean toward selling, a net 40,487 shares.
Teresa L. Young has 18 Form 4 filings on record from June 2020 to February 2026, all as Seres Therapeutics (MCRB), 2020–2026.
The 41 reported transactions were 17 option exercises, 12 open-market sales and 12 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 12 sales worth about $61K.
The largest open-market sale was 24,480 shares of MCRB at an average $1.08 on August 5, 2024, about $27K. Twelve months later MCRB was down 44%.
All 12 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2026 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 75 | $8.47 | $635.25 | -0.9% | -7.7% | - | |
| Nov 15, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 1,042 | $17.30 | $18,026.60 | -11.0% | -49.2% | - | |
| Aug 18, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 59 | $16.65 | $982.35 | -1.1% | +22.3% | -75.5% | |
| May 16, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 63 | $7.28 | $458.64 | -1.2% | +126.0% | +2.4% | |
| Feb 18, 2025 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 3,338 | $0.81 | $2,704.45 | -3.3% | -52.0% | -50.5% | |
| Nov 18, 2024 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 735 | $0.54 | $397.64 | -0.8% | +43.6% | +113.4% | |
| Oct 28, 2024 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 2,983 | $0.69 | $2,058.57 | -3.3% | +20.2% | +22.6% | |
| Aug 16, 2024 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 728 | $0.84 | $611.52 | -0.9% | -32.7% | -5.1% | |
| Aug 5, 2024 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 24,480 | $1.08 | $26,533.87 | -23.8% | -36.9% | -44.2% | |
| May 15, 2024 | MCRB Seres Therapeutics, Inc. | See Remarks | Sale+OE10b5-1 | 703 | $0.94 | $660.82 | -3.8% | -13.6% | -61.3% |